Emerging Mechanisms and the Future of Multiple Sclerosis Treatment

In Emerging Mechanisms and the Future of Multiple Sclerosis Treatment, Millad Sobhanian, PharmD, BCPS, and Kiranpal Sangha, PharmD, delve into novel therapeutic mechanisms beyond BTK inhibitors and how these innovations may reshape the MS treatment landscape over the next five years.

The therapeutic landscape of multiple sclerosis (MS) continues to evolve rapidly, with researchers exploring novel mechanisms of action beyond Bruton's tyrosine kinase inhibitors (BTKis) to address unmet needs in disease management. Emerging therapies under investigation aim to target neuroinflammation, remyelination, and neuroprotection, moving beyond traditional relapse-focused approaches. Innovative strategies include agents that modulate microglial activity, promote repair of damaged myelin, and protect against axonal degeneration. These mechanisms hold the potential to slow or prevent long-term disability, even in patients who show minimal inflammatory activity on conventional imaging or clinical assessments.

Looking ahead, the MS treatment paradigm is expected to become increasingly personalized, integrating biologically driven therapies with advanced biomarkers for early detection and disease monitoring. Combination approaches that address both inflammation and neurodegeneration may become more common, and treatment algorithms are likely to evolve to incorporate new options for progressive or smoldering disease. Additionally, improved understanding of disease heterogeneity will enable clinicians to tailor therapy selection based on individual patient risk profiles and disease activity. Overall, the next five years are poised to bring a shift from predominantly relapse-focused care to a more comprehensive, mechanism-based strategy aimed at preserving long-term neurologic function and enhancing quality of life for patients living with MS.

Led by Jacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS, neurology pharmacists examine the following critical questions:

Beyond BTKi’s, are there any mechanisms of action currently under investigation that you are excited about?

How do you foresee the treatment landscape of MS changing in the next 5 years?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, The Expanding Role of Pharmacists in Patient Education and REMS Management in Multiple Sclerosis, further explores multiple sclerosis, highlighting the pharmacist’s role in educating patients with MS—including those with nrSPMS—about disease progression and treatment, while leveraging experience with REMS programs to support the safe use of current and emerging therapies such as BTK inhibitors.